SRR650202
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.630
- G2M_CHECKPOINT+0.560
- MYC_TARGETS_V2+0.440
- MYC_TARGETS_V1+0.390
- SPERMATOGENESIS+0.290
- MITOTIC_SPINDLE+0.260
- DNA_REPAIR+0.110
- PROTEIN_SECRETION+0.100
- PI3K_AKT_MTOR_SIGNALING+0.090
- UNFOLDED_PROTEIN_RESPONSE+0.090
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
- ALLOGRAFT_REJECTION-0.450
- COAGULATION-0.440
- COMPLEMENT-0.440
- KRAS_SIGNALING_UP-0.440
- UV_RESPONSE_DN-0.440
- INFLAMMATORY_RESPONSE-0.430
- APOPTOSIS-0.420
- INTERFERON_GAMMA_RESPONSE-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR650141 | — | — | 0.941 |
| 2 | MNG704 | — | — | 0.936 |
| 3 | TCGA-66-2793-01A-01R-1201-07 | — | cohortMD1 | 0.928 |
| 4 | C3L-04013 | — | cohortMD1 | 0.928 |
| 5 | TCGA-E7-A5KE-01A-11R-A28M-07 | — | — | 0.926 |
| 6 | BS_9V633J1X | medulloblastoma | — | 0.924 |
| 7 | BS_QHS3V0GP | Embryonal tumors | — | 0.924 |
| 8 | SRR650205 | — | — | 0.922 |
| 9 | 24975492-6b9f-445b-9f6b-daee2f8363d3 | — | — | 0.922 |
| 10 | 085e4228-8ed7-44d7-9ab5-8a096434b650 | — | — | 0.921 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.630 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.040 | Inavolisib | — uncovered |